Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer

Jun Murakami, Jun-Ichi Asaumi, Noriko Kawai, Hidetsugu Tsujigiwa, Yoshinobu Yanagi, Hitoshi Nagatsuka, Tetsuyoshi Inoue, Susumu Kokeguchi, Shoji Kawasaki, Masahiro Kuroda, Noriaki Tanaka, Nagahide Matsubara, Kanji Kishi

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

We speculated whether or not the expression level of telomerase reverse transcriptase (hTERT) would be modulated by agents targeting epigenetics in oral cancer cell lines. Although hTERT is known to be targeted by epigenetic changes, it remains unclear how chemoagents targeting epigenetics work on hTERT transcription. In the present study, the epigenetic effects of the histone deacetylase (HDAC) inhibitor FR901228 on hTERT transcription in oral cancer cell lines were analyzed by RT-PCR. The mRNA expression of hTERT was upregulated after exposure to FR901228 in hTERT-negative Hep2 cells, and even SAS and KB cells expressed high levels of hTERT. Moreover, cotreatment of protein synthesis inhibitor cycloheximide (CHX) resulted in the induction of hTERT transcription by FR901228. This suggests that the induction of hTERT by FR901228 requires de novo protein synthesis to some extent and is more likely a direct than an indirect effect on epigenetic changes such as histone acetylation/deacetylation. We further examined the effect of FR901228 on c-myc protein, which is one of the main hTERT transcription activators. FR901228 repressed c-myc protein only in the absence of CHX, and depended on the enhancement of de novo protein synthesis. Our results indicate that c-myc protein is repressed indirectly by FR901228 but may not contribute to FR901228-induced hTERT transcription. The present study showed that the HDAC inhibitor FR901228 induced the hTERT gene by a complex mechanism that involved transcription factors other than c-myc, in addition to inhibition of histone deacetylation.

Original languageEnglish
Pages (from-to)22-28
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume56
Issue number1
DOIs
Publication statusPublished - Jul 2005

Fingerprint

Histone Deacetylase Inhibitors
Mouth Neoplasms
Telomerase
Transcription
Epigenomics
Proto-Oncogene Proteins c-myc
Cycloheximide
Histones
Cells
KB Cells
romidepsin
Cell Line
Acetylation
Protein Synthesis Inhibitors
Proteins
Transcription Factors
Genes
Polymerase Chain Reaction
Messenger RNA

Keywords

  • FR901228
  • HDAC inhibitor
  • hTERT
  • Oral cancer

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer. / Murakami, Jun; Asaumi, Jun-Ichi; Kawai, Noriko; Tsujigiwa, Hidetsugu; Yanagi, Yoshinobu; Nagatsuka, Hitoshi; Inoue, Tetsuyoshi; Kokeguchi, Susumu; Kawasaki, Shoji; Kuroda, Masahiro; Tanaka, Noriaki; Matsubara, Nagahide; Kishi, Kanji.

In: Cancer Chemotherapy and Pharmacology, Vol. 56, No. 1, 07.2005, p. 22-28.

Research output: Contribution to journalArticle

Murakami, Jun ; Asaumi, Jun-Ichi ; Kawai, Noriko ; Tsujigiwa, Hidetsugu ; Yanagi, Yoshinobu ; Nagatsuka, Hitoshi ; Inoue, Tetsuyoshi ; Kokeguchi, Susumu ; Kawasaki, Shoji ; Kuroda, Masahiro ; Tanaka, Noriaki ; Matsubara, Nagahide ; Kishi, Kanji. / Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer. In: Cancer Chemotherapy and Pharmacology. 2005 ; Vol. 56, No. 1. pp. 22-28.
@article{4fe4bc9310b84f83868423687e358a1a,
title = "Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer",
abstract = "We speculated whether or not the expression level of telomerase reverse transcriptase (hTERT) would be modulated by agents targeting epigenetics in oral cancer cell lines. Although hTERT is known to be targeted by epigenetic changes, it remains unclear how chemoagents targeting epigenetics work on hTERT transcription. In the present study, the epigenetic effects of the histone deacetylase (HDAC) inhibitor FR901228 on hTERT transcription in oral cancer cell lines were analyzed by RT-PCR. The mRNA expression of hTERT was upregulated after exposure to FR901228 in hTERT-negative Hep2 cells, and even SAS and KB cells expressed high levels of hTERT. Moreover, cotreatment of protein synthesis inhibitor cycloheximide (CHX) resulted in the induction of hTERT transcription by FR901228. This suggests that the induction of hTERT by FR901228 requires de novo protein synthesis to some extent and is more likely a direct than an indirect effect on epigenetic changes such as histone acetylation/deacetylation. We further examined the effect of FR901228 on c-myc protein, which is one of the main hTERT transcription activators. FR901228 repressed c-myc protein only in the absence of CHX, and depended on the enhancement of de novo protein synthesis. Our results indicate that c-myc protein is repressed indirectly by FR901228 but may not contribute to FR901228-induced hTERT transcription. The present study showed that the HDAC inhibitor FR901228 induced the hTERT gene by a complex mechanism that involved transcription factors other than c-myc, in addition to inhibition of histone deacetylation.",
keywords = "FR901228, HDAC inhibitor, hTERT, Oral cancer",
author = "Jun Murakami and Jun-Ichi Asaumi and Noriko Kawai and Hidetsugu Tsujigiwa and Yoshinobu Yanagi and Hitoshi Nagatsuka and Tetsuyoshi Inoue and Susumu Kokeguchi and Shoji Kawasaki and Masahiro Kuroda and Noriaki Tanaka and Nagahide Matsubara and Kanji Kishi",
year = "2005",
month = "7",
doi = "10.1007/s00280-004-0976-x",
language = "English",
volume = "56",
pages = "22--28",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer

AU - Murakami, Jun

AU - Asaumi, Jun-Ichi

AU - Kawai, Noriko

AU - Tsujigiwa, Hidetsugu

AU - Yanagi, Yoshinobu

AU - Nagatsuka, Hitoshi

AU - Inoue, Tetsuyoshi

AU - Kokeguchi, Susumu

AU - Kawasaki, Shoji

AU - Kuroda, Masahiro

AU - Tanaka, Noriaki

AU - Matsubara, Nagahide

AU - Kishi, Kanji

PY - 2005/7

Y1 - 2005/7

N2 - We speculated whether or not the expression level of telomerase reverse transcriptase (hTERT) would be modulated by agents targeting epigenetics in oral cancer cell lines. Although hTERT is known to be targeted by epigenetic changes, it remains unclear how chemoagents targeting epigenetics work on hTERT transcription. In the present study, the epigenetic effects of the histone deacetylase (HDAC) inhibitor FR901228 on hTERT transcription in oral cancer cell lines were analyzed by RT-PCR. The mRNA expression of hTERT was upregulated after exposure to FR901228 in hTERT-negative Hep2 cells, and even SAS and KB cells expressed high levels of hTERT. Moreover, cotreatment of protein synthesis inhibitor cycloheximide (CHX) resulted in the induction of hTERT transcription by FR901228. This suggests that the induction of hTERT by FR901228 requires de novo protein synthesis to some extent and is more likely a direct than an indirect effect on epigenetic changes such as histone acetylation/deacetylation. We further examined the effect of FR901228 on c-myc protein, which is one of the main hTERT transcription activators. FR901228 repressed c-myc protein only in the absence of CHX, and depended on the enhancement of de novo protein synthesis. Our results indicate that c-myc protein is repressed indirectly by FR901228 but may not contribute to FR901228-induced hTERT transcription. The present study showed that the HDAC inhibitor FR901228 induced the hTERT gene by a complex mechanism that involved transcription factors other than c-myc, in addition to inhibition of histone deacetylation.

AB - We speculated whether or not the expression level of telomerase reverse transcriptase (hTERT) would be modulated by agents targeting epigenetics in oral cancer cell lines. Although hTERT is known to be targeted by epigenetic changes, it remains unclear how chemoagents targeting epigenetics work on hTERT transcription. In the present study, the epigenetic effects of the histone deacetylase (HDAC) inhibitor FR901228 on hTERT transcription in oral cancer cell lines were analyzed by RT-PCR. The mRNA expression of hTERT was upregulated after exposure to FR901228 in hTERT-negative Hep2 cells, and even SAS and KB cells expressed high levels of hTERT. Moreover, cotreatment of protein synthesis inhibitor cycloheximide (CHX) resulted in the induction of hTERT transcription by FR901228. This suggests that the induction of hTERT by FR901228 requires de novo protein synthesis to some extent and is more likely a direct than an indirect effect on epigenetic changes such as histone acetylation/deacetylation. We further examined the effect of FR901228 on c-myc protein, which is one of the main hTERT transcription activators. FR901228 repressed c-myc protein only in the absence of CHX, and depended on the enhancement of de novo protein synthesis. Our results indicate that c-myc protein is repressed indirectly by FR901228 but may not contribute to FR901228-induced hTERT transcription. The present study showed that the HDAC inhibitor FR901228 induced the hTERT gene by a complex mechanism that involved transcription factors other than c-myc, in addition to inhibition of histone deacetylation.

KW - FR901228

KW - HDAC inhibitor

KW - hTERT

KW - Oral cancer

UR - http://www.scopus.com/inward/record.url?scp=21244453835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244453835&partnerID=8YFLogxK

U2 - 10.1007/s00280-004-0976-x

DO - 10.1007/s00280-004-0976-x

M3 - Article

C2 - 15791453

AN - SCOPUS:21244453835

VL - 56

SP - 22

EP - 28

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -